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ABSRACT
In the perspective of reaching at least 75% inﬂuenza vaccination coverage in the elderly and substantial budget
constraints, Italian decision makers are facing important challenges in determining an optimal immunization
strategy for this growing and particularly vulnerable population. Four different inﬂuenza vaccines are currently
available for Italian older adults aged 65 years or above, namely trivalent inactivated vaccines (TIVs),
MF59-adjuvanted TIV (MF59-TIV), intradermal TIV (ID-TIV) and quadrivalent inactivated vaccines (QIVs). The
present study is the ﬁrst to compare the cost-effectiveness proﬁles of virtually all possible public health
strategies, including the aforementioned four vaccine formulations as well non-vaccination. For this purpose, a
decision tree model was built ex novo; the analysis was conducted from the third-payer perspective in the
timeframe of one year. All available vaccines were cost-effective compared with non-vaccination. However,
MF59-TIV had the most favorable economic proﬁle in the Italian elderly population. Indeed, compared with
non-vaccination, it was deemed highly cost-effective with an incremental cost-effectiveness ratio (ICER) of
€10,750 per quality-adjusted life year (QALY). The ICER was much lower (€4,527/QALY) when MF59-TIV was
directly compared with TIV. ID-TIV and QIV were dominated by MF59-TIV as the former comparators were
associated with greater total costs and lower health beneﬁts. Both deterministic and probabilistic sensitivity
analyses conﬁrmed robustness of the base case results. From the economic perspective, MF59-TIV should be
considered as a preferential choice for Italian older adults aged 65 years or above.
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Introduction
Every season inﬂuenza affects 10–20% of the population.1
Inﬂuenza attack rate is usually signiﬁcantly higher in children
and adolescents; however, most hospitalizations and about 90%
of inﬂuenza-attributable deaths, which may be considered as
major cost drivers, occur among older adults aged 65 years.2
Annual inﬂuenza vaccination remains the primary public
health measure able to prevent infection, diminish inﬂuenza-
associated complications, hospitalizations and deaths and thus,
reduce the burden of diseas;e3 this is the reason why virtually
all industrialized and many developing countries recommend
the annual vaccination for the elderly and other high-risks
groups.4,5 Despite this, vaccination coverage (VC) among the
elderly persists at relatively low levels in most countries.4
It is well-recognized that, compared with non-vaccination,
annual inﬂuenza immunization is cost-effective or even cost-sav-
ing in different settings and population groups including the
elderly (For a review, see6). However, the landscape of available
inﬂuenza vaccines is changing continuously. For instance, in Italy
four different types of vaccine are currently commercially avail-
able and indicated for immunization of the elderly: trivalent
inactivated vaccines (TIVs), MF59-adjuvanted TIV (MF59-TIV),
intradermal TIV (ID-TIV) and quadrivalent inactivated vaccines
(QIVs). These vaccines differ in several aspects including
manufacturing processes, contents, route of administration, strain
coverage, and vaccine effectiveness (VE).7,8
Among the aforementioned vaccine formulations, MF59-TIV
was the ﬁrst speciﬁcally designed to overcome the phenomenon
of immunesenescence.9 First licensed in 1997 in Italy, MF59-
TIV has consistently been shown to be superior to traditional
vaccines in terms of immunogenicity and ﬁeld effectiveness in
tens of clinical trials and observational studies (For reviews, see
refs. 10–13). Twenty years of widespread use in the general pop-
ulation, regulatory approval in approximately 30 countries, and
several economic evaluations,14–20 have all established a favor-
able economic proﬁle of MF59-TIV.
Given the objective to reach at least 75% inﬂuenza VC in the
elderly,21 the steady increasing size of the elderly population,22
issues around the vaccine hesitancy,23 the increasing ﬁnancial
pressure on the public health sector24 and the ready availability
of four different vaccines, Italian decision makers are facing sig-
niﬁcant challenges in deﬁning an optimal immunization strat-
egy. Existing Italian economic evaluations do not precisely
reﬂect the current market situation, in that the previous
elderly-speciﬁc research compared few options. The economic
evaluations of all possible strategies may undoubtedly aid or
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even guide critical decisions; in this view, the present study
aimed to compare all seasonal inﬂuenza vaccines available in
Italy for immunization of the elderly in terms of cost-effective-
ness (CE).
Results
Base case
Table 1 shows average absolute and incremental costs and
effectiveness (quality-adjusted life years – QALYs) per person,
and the corresponding incremental cost-effectiveness ratios
(ICERs). It is evident that the “do nothing” strategy is less
expensive but, at the same time, the least effective. Immunizing
Italian elderly individuals with TIV would produce an incre-
mental cost of €4.69 and an incremental beneﬁt of approxi-
mately 4 hours (DQALY per person D 0.000381, i.e. ca 5,000
QALYs per total cohort) in perfect health. From the Italian
National Healthcare Service (NHS) perspective, this investment
would be advisable, given the ICER €12,305/QALY gained.
When directly comparing TIV and MF59-TIV, the latter was
demonstrated to be highly cost-effective with an ICER of
€4,527/QALY. By contrast, two other competitors (ID-TIV and
QIV) were dominated by MF59-TIV. The head-to-head com-
parison of MF59-TIV with non-vaccination was also highly
cost-effective with an ICER of €10,750/QALY. Similarly, both
ID-TIV and QIV were cost-effective compared with non-vacci-
nation with ICERs of €11,960/QALY and €19,655/QALY,
respectively.
One-way sensitivity analysis
In the one-way sensitivity analysis of MF59-TIV vs TIV, only
few input parameters had a signiﬁcant impact on ICER. The
ﬁrst parameter was TIV VE. When the lower limit estimate
(34%) was used, TIV was dominated by MF59-TIV, while set-
ting this parameter to the higher limit (73%) produced a dia-
metrically opposite outcome in that TIV became a dominant
strategy. The second parameter was MF59-TIV VE: at the max-
imum level ICER was €222/QALY, while at minimum levels it
grew up to €119,477/QALY. Finally, vaccine price was able to
largely change the outcome: at the minimal TIV price ICER
became €24,479/QALY, while at the maximum acquisition cost
of TIV, MF59-TIV was a dominant strategy.
The second deterministic analysis, i.e. MF59-TIV vs non-
vaccination revealed a higher number of parameters able to
inﬂuence the ICER in a substantial manner. These included:
inﬂuenza attack rate, VE, vaccine price, administration cost,
and QALY loss due to inﬂuenza. However, the min-max varia-
tion of this parameters resulted in ICERs ranging in a plausible
interval (from €5,104 to €19,358 per QALY gained), i.e. well
below the threshold of €30,000/QALY.
Probabilistic sensitivity analysis (PSA)
Fig. 1 shows the acceptability curves of the four vaccines and
the non-vaccination option. At the threshold of €30,000/
QALY, MF59-TIV has the probability of 58.8% to be the best
choice, ID-TIV – 25.5%, while TIV and QIV remained perma-
nently excluded (i.e. dominated).
The comparison between MF59-TIV and TIV is illustrated
in Fig. 2 with the CE plane. As illustrated, MF59-TIV remains
cost-effective with an ICER below €30,000/QALY in 58.3% of
simulations, exceeds €30.000/QALY only in 13.1%, and in
18.1% is dominant. MF59-TIV is dominated by TIV in the
remaining 10.5% of cases.
The probabilistic sensitivity analysis (PSA) of the compari-
son between MF59-TIV and non-vaccination is shown in
Fig. 3. In 80.9% of the simulations, MF59-TIV is below the
threshold value while it exceeds this value in 17.3% of cases. In
1.8% of cases it is dominant.
The sensitivity analysis concludes that the results of the base
case are robust.
Discussion
To the best of our knowledge, the present paper is the ﬁrst
study that compared all available alternatives for the immuni-
zation of Italian elderly individuals; even in the international
context, a few studies used more than two competitors. Here
we established the fact that MF59-TIV had the most favorable
CE proﬁle among all existing, commercially available alterna-
tives for the elderly in Italy. Indeed, compared with non-vacci-
nation, MF59-TIV was highly cost-effective: the ICER was
€10,750/QALY, which is well below all existing thresholds. A
universal substitution of TIV with MF59-TIV in the Italian
elderly population is highly advisable, given the ICER of less
than €5,000/QALY. At the same time, our analyses showed
that, compared with MF59-TIV, the universal use of ID-TIV
and QIV among the elderly would produce greater cost and
decreased health beneﬁts (i.e. MF59-TIV was dominant).
Our sensitivity analysis highlighted the robustness of the
base case results. In particular, in the one-way simulation
where MF59-TIV was compared with non-vaccination, no
ICER estimates exceeded €30,000/QALY. When MF59-TIV
was compared with TIV, it emerged that the VE of both
Table 1. Base case cost-effectiveness analysis of different seasonal inﬂuenza vaccination strategies among the Italian elderly population.
Strategy Cost, € Incremental cost, € Effectiveness, QALY Incremental effectiveness, QALY£ 103 ICER, €/QALY
Non-vaccination 6.23 — 8.960458 — —
TIV 10.92 4.69 8.960839 0.381 12,305
MF59-TIV 11.35 0.43 8.960935 0.095 4,527
ID-TIV 11.54 0.19 8.960902 Negative Dominated
QIV 14.21 2.86 8.960864 Negative Dominated
Abbreviations: ICER, incremental cost-effectiveness ratio; ID-TIV, intradermal trivalent inactivated vaccine; MF59-TIV, MF59-adjuvanted trivalent inactivated vaccine; QALY,
quality-adjusted life year; QIV, quadrivalent inactivated vaccine.
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vaccines was the main driver of ICER. However, two points
are noteworthy here. First, it is highly unlikely that TIV may
have a greater VE than MF59-TIV since no study published so
far has established the superiority of TIV over MF59-TIV in
terms of both immunogenicity and effectiveness; by contrast,
several meta-analyses10-13,25 have demonstrated MF59-TIV
to provide better protection than non-adjuvanted TIV. Sec-
ond, the relative VE of MF59-TIV of 25% adopted in the pres-
ent analysis is likely to be an underestimate: a study by Van
Buynder et al.26 demonstrated MF59-TIV to have a relative
VE compared with TIV of 63% against laboratory-conﬁrmed
inﬂuenza.
While the univariate sensitivity analysis allows for the iden-
tiﬁcation of the main drivers of the pharmacoeconomic out-
come, it undoubtedly underestimates the uncertainty level
around ICER since it assumes that this uncertainty is relative to
only one parameter at one time. This shortcoming was
addressed by PSA: MF59-TIV was cost-effective or cost-saving
in 76% and 83% of simulations when directly compared with
TIV and “do nothing”, respectively. These probabilities are
very high. Indeed, it has been shown27 that health technologies
with at least 40% probability of being cost-effective in PSA
tended to be recommended by the National Institute for Health
and Care Excellence (NICE).
Figure 1. Cost-effectiveness acceptability curves of all ﬁve study strategies.
Figure 2. Cost-effectiveness plane of the probabilistic sensitivity analysis (10,000 rounds): MF59-adjuvanted trivalent inactivated vaccine (MF59-TIV) versus trivalent inacti-
vated vaccine (TIV).
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The results of the present analyses should be compared with
previously published Italian studies15,17 ;however, these studies
compared only two strategies, namely “MF59-TIV vs non-vac-
cination” and “MF59-TIV vs TIV”. Regarding these two strate-
gies, our results are similar in that MF59-TIV is cost-effective.
On the other hand, in the previous research MF59-TIV has
been found not only to be cost-effective but also cost-saving
compared with both TIV and “do nothing”. The explanation is
likely to be connected to the model assumptions that were
more conservative in the present analysis. For instance, here we
used the laboratory-conﬁrmed infection as inﬂuenza-related
outcome, while the previous models used inﬂuenza-like illness
(ILI) and other inﬂuenza proxies; given that the inﬂuenza node
is in the beginning of the decision tree, all consecutive parame-
ters like hospitalizations and deaths decreased substantially.
Similarly, although we adjusted the hospitalization rate by the
laboratory test sensitivity, this parameter may be still underesti-
mated since only a small amount of the hospitalized elderly
underwent laboratory assessment. In this regard, Reed et al.28
have calculated that the observed number of inﬂuenza-related
hospitalizations should be multiplied by a factor of 5.2.
If we consider international CE evaluations,14,16,18,20 our
results still remain in a highly plausible range. A French
model by Piercy et al.14 has demonstrated that the use of
MF59-TIV instead of TIV among the high-risk elderly popu-
lation is cost-effective, with however, some (sub)type variabil-
ity in the ICERs (€17,496, €3,759 and €4,821 per life year
gained for A/H1N1, A/H3N2 and B, respectively). In Canada,
the substitution of TIV with MF59-TIV in the elderly was
highly cost-effective (ICER D $2,111/QALY).16 A more recent
CE analysis by Mullikin et al.18 was conducted from the
United States (US) perspective, where the universal seasonal
inﬂuenza recommendation is in place. Their model compared
various public health strategies, in which different vaccines
were offered to different age categories. From these data, it
seems that the most attractive strategy would be the use of
MF59-TIV among the elderly and QIV among the younger
age groups. Finally, a very recent United Kingdom (UK) CE
analysis20 has reached similar results: MF59-TIV is cost-effec-
tive with an ICER of £3,540 (approximately €4,000/QALY), if
used preferentially to current UK immunization practice
among 65-year-olds. The previous ﬁndings underline that
our ICER estimates may be generalizable.
Particular attention should be paid to the use of the recently
marketed QIV in the elderly. QIV is undoubtedly a further and
important step towards a universal inﬂuenza vaccine. However,
the relatively low impact of B type inﬂuenza in the Italian
elderly population,29 the suboptimal protection provided by
non-adjuvanted vaccines10,30 and the relatively high acquisition
cost,31 may have lowered the CE proﬁle of QIV. We would like
to discuss that our imputation approach to determine a relative
advantage of the second B strain is likely to be overestimated in
older adults for two reasons. First, we used in-house 13-season
data on the distribution of types A and B among the elderly
and these came from a single North Italian region. The selected
parameter of 17.9% may have overestimated the national
multi-season average of the relative frequency of type B among
the elderly by as much as 3 times. Indeed, the Global Inﬂuenza
B Study29 has established that in Italy the average isolation rate
of type B among seniors is only about 5%. Second, the assumed
reduction of TIV VE may also be overestimated. The recent
meta-regression analysis,32 that investigated both immunoge-
nicity-derived estimates of VE and ﬁeld VE, has documented
that the impact of B lineage mismatch may be high in very
young populations (up to 73%) but it is negligible in the elderly
(about 3%). From the economic perspective, these thoughts are
corroborated with a recently published UK CE analysis33; this
study shows that QIV may be cost-effective in all target groups.
However, QIV may be cost-effective in children with an
increased cost per dose of up to £6.36, while the program
Figure 3. Cost-effectiveness plane of the probabilistic sensitivity analysis (10,000 rounds): MF59-adjuvanted trivalent inactivated vaccine (MF59-TIV) versus no vaccination.
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extension to all elderly would admit an increase of only £0.20
per dose. Therefore, we believe that the current Italian market
of inﬂuenza vaccines and tender policies should be differenti-
ated according to the age of the target groups. In fact, in the US
study by Mullikin et al.18 it has been established that the immu-
nization strategy in which people below 65 years are vaccinated
with QIV and the elderly with MF59-TIV is the most cost-
effective. Considering that at the European level there is some
tendency to extend the vaccination offer to other population
groups34-36 and the fact that the price of QIV may drop in the
near future, it will be useful to carry out a differentiated CE
modeling approach like that of Mullikin et al.18
Another suggestion for future economic research resides in
the modelling of co-administration of inﬂuenza and pneumo-
coccal vaccines. This would be of relevance for Italian decision
makers and other stakeholders given that the most recent
2017–2019 National Immunization Plan37 explicitly recom-
mends the pneumococcal vaccination for people aged 65 years
and above. Indeed, these vaccines may provide a synergistic
effect by further reducing numbers of hospitalizations and
deaths38 compared with strategies when administered alone.
Clinical trials have suggested that both vaccines may be safely
co-administered in different arms. For instance, the co-admin-
istration of MF59-TIV with either 13-valent pneumococcal
conjugate vaccine (PCV-13)39 or 23-valent pneumococcal poly-
saccharide vaccine (PPV-23)40 did not produce any immuno-
logical inference or signiﬁcantly increased reactogenicity. Given
that both inﬂuenza6 and pneumococcal vaccines41,42 are highly
cost-effective, the economic proﬁle of their co-administration
could be even more attractive.
Like all CE studies the present one is not without limitations
that should be taken into account during the interpretation of
our ﬁndings. In the previous paragraphs as well as in the “Meth-
ods” section we already discussed some issues around the under-
estimation of our input parameters; however, we actually
consider these shortcomings to be study strengths, because we
showed that each available inﬂuenza vaccine is cost-effective even
at conservative assumptions (the authors favored a conservative
approach). Possible study limitations include the fact that, some
input parameters such as complications, hospitalizations and
mortality following an inﬂuenza episode were not conducted in
Italy but in the UK or US. The scoping review conducted during
a health technology assessment (HTA) did not allow us to iden-
tify any Italian study that would have reported representative and
robust data on the parameters of interest. However, we believe
that the selected parameters may be applied to the Italian situa-
tion with a great conﬁdence, since they came from relatively large
studies and it is plausible to hypothesize that the clinical course of
laboratory-conﬁrmed inﬂuenza is similar in industrialized coun-
tries. In any case, the surrounding uncertainty was addressed by
performing sensitivity analyses with adequate ranges. Second,
our model considers an average VE and thus does not distinguish
among single (sub)types. Piercy et al.14 have shown that MF59-
TIV has the lowest ICER vs TIV in the case of the A/H3N2 sub-
type. This is highly plausible because A/H3N2, which has a rela-
tively high mutation rate, causes the majority of the socio-
economic inﬂuenza-associated burden in the elderly43,44 and
MF59-TIV may provide signiﬁcantly better protection against
drifted A/H3N2 strains than TIV.25 The recent statistical
estimation45 of the (sub)type-speciﬁc relative VE has established
that MF59-TIV may be more effective than TIV by 33%, 44%,
12% and 37%, 33%, 8% against A/H1N1, A/H3N2 and B homol-
ogous and heterologous strains, respectively. Considering these
data and the fact that A/H3N2 is responsible for the majority of
the inﬂuenza burden in the Italian elderly population,43,44 our
input parameter of 25% is likely to be underestimated. And third
(but not least), in the present study we adopted the third payer
perspective that undoubtedly underestimates reality since it does
not consider indirect costs. Although it is often considered that
the elderly have a relatively low societal capital because most of
them are retired, they may undoubtedly contribute to the reduc-
tion of indirect costs generated by inﬂuenza epidemics (e.g.
grandparents look after grandchildren). This is particularly actual
in the view in the “Healthy Ageing” initiatives undertaken thor-
ough the world.
In conclusion, annual inﬂuenza vaccination dramatically
reduces the burden of disease among the Italian elderly pop-
ulation; urgent actions should be undertaken in order to
increase VC. From the economic perspective, it seems that
MF59-TIV should be preferentially recommended to older
adults in Italy.
Methods
Overview of the study objectives, model, outcome
and reporting
The selection of model input parameters was driven by both
systematic/scoping reviews conducted during a recently per-
formed HTA of MF59-TIV46 and expert opinion. Italy-speciﬁc
data were always preferred providing that they were available
and speciﬁc to and representative of the target population.
A novel decision tree model was constructed (TreeAge Pro
2017, TreeAge Software Inc.) in order to model the CE of dif-
ferent vaccination strategies among the Italian elderly. In order
to reﬂect the National recommendations,47 a cut-off of 65 years
was used for the deﬁnition of the elderly. A total of ﬁve differ-
ent strategies were compared: TIV, MF59-TIV, ID-TIV, QIV
and non-vaccination. A stylized, simpliﬁed version of the deci-
sion tree is reported in Fig. 4. Brieﬂy, every individual belong-
ing to the low- or high-risk sub-cohorts (see below) that enters
the model may receive either vaccine (according the probability
of being immunized) or no vaccination. The risk of contracting
inﬂuenza will depend on both the baseline attack rate and vac-
cine type (i.e. VE). Inﬂuenza-positive subjects may develop
complications treatable at either outpatient or inpatient regi-
mens. In turn, the hospitalized patients may die or survive.
The study was conducted from the perspective of the Italian
NHS. The time horizon was set to one year to reﬂect a single
inﬂuenza season; for this reason, no discount rates were applied
to costs. However, life expectancy for individuals entering the
model was estimated in order to take into account beneﬁts
associated with deaths avoided due to vaccination. To do this,
the loss of QALYs due to death was calculated by using the
average life expectancy in Italy and age-speciﬁc utility for the
elderly. The outcome of the model was the incremental cost per
QALY gained (ICER); all costs were reported in 2017 Euros
(€), while the measure of effects was expressed as QALYs.
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The reporting is compliant with the Consolidated Health Eco-
nomic Evaluation Reporting Standards (CHEERS) checklist.48
Demographic, epidemiological and clinical input
parameters
Study population. The target population included a cohort of
Italian individuals aged 65 and above; the cohort size was
13,369,754 corresponding to 22% of the whole population.49 Con-
sidering that the presence of underlying chronic conditions is a
well-recognized50-53 risk factor for developing serious inﬂuenza-
related complications and consequent hospitalizations, the whole
cohort was split into two groups, namely “low-risk” and “high-
risk”. The probability of belonging to low- and high-risk categories
was set to 55.9% and 44.1%, respectively. These estimates derive
from an elaboration of the National Institute of Statistics54 that
report the frequency of at least one serious chronic medical condi-
tion among people aged 65 years. The following chronic condi-
tions are deﬁned as serious: diabetes, myocardial infarction,
angina pectoris, other cardiac diseases, stroke, intracerebral hem-
orrhage, chronic bronchitis, emphysema, cirrhosis, malignancies
(including lymphoma and leukemia), parkinsonism, Alzheimer’s
disease and dementia. Of note, the aforementioned chronicities
are similar to the list of conditions (reported annually by the Ital-
ianMinistry of Health),47 for which seasonal vaccination is recom-
mended. Moreover, the estimates are in line with Italy-speciﬁc
elaborations reported by Ryan et al.55 and used in previous Italian
economic evaluations.31 For the sensitivity analysis a variation of
§20% was considered plausible.
Vaccination coverage. To the best of our knowledge, now-
adays there are no publicly available Italian population-based
data on VC among the low- and high-risk elderly. However, it
is unlikely that these two population groups have the same
probability of being immunized. Indeed, the systematic review
by Yeung et al.56 has highlighted that the presence of a
chronic condition is an independent predictor of vaccine
uptake. To ﬁnd out risk-speciﬁc VC rates we proceeded as fol-
lows. First, an average VC of the last ten seasons (excluding
the pandemic season) in the whole elderly population57 was
computed, being 59.9%. Then, we calculated an approximate
20% more chance to adhere to seasonal vaccination among
the high-risk elderly.58 Therefore, the risk-speciﬁc VCs were
imputed by solving the following equation: (Plow risk £ c) C
[Phigh risk £ (1.2£ c)] D 59.9%, where c is VC among the low-
risk elderly. This resulted in VC rates of 55.1% and 66.0% for
the low- and high-risk elderly, respectively. To account for the
between-season variability in VC, a variation of §20% was
used in the sensitivity analysis.
Laboratory-conﬁrmed inﬂuenza attack rates. Similar to the
previous parameter, we failed to identify the inﬂuenza attack
rate (i.e. baseline risk) among non-vaccinated Italian elderly
individuals from a single source. Therefore, the parameter was
imputed using the following methodology. First, we used a
meta-analytic estimate of 16.8% (95% CI: 6.6–33.1%) obtained
through pooling of the ILI attack rate among the non-vacci-
nated Italian elderly.17 We then examined all available seasonal
(seven consecutive seasons excluding the pandemic) virus isola-
tion rates routinely collected by the Italian virological surveil-
lance system InﬂuNet.59 On average, 32.1% of isolates from ILI
patients were inﬂuenza positive. The probability of inﬂuenza
was therefore computed as a product of ILI attack rate and
average virus isolation rate, being 5.4% (range: 2.1–10.6%). It
was assumed that the elderly at low and high risk for inﬂuenza
complications have the same inﬂuenza attack rates. Our input
parameter is also perfectly in line with the estimate of 5.7%
derived from a meta-analysis of placebo arms in Randomized
Controlled Trials (RCTs) enrolling the elderly and used in pre-
vious economic evaluations.60
Figure 4. Simpliﬁed version of the decision tree.
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Inﬂuenza-related complications. A total of eight different
complications [bronchitis, pneumonia, unspeciﬁed respiratory
tract infection (URTI), otitis media, gastrointestinal (GI) bleed-
ing, cardiovascular, central nervous system (CNS), and renal]
attributable to inﬂuenza were considered (Table 2); their proba-
bilities (both point estimates and 95% CIs) were extracted from
Meier et al.53
Care seeking and hospitalizations. The probability of care
seeking during an ILI episode among Italian elderly individuals
has recently been quantiﬁed by Perotta et al.61 These authors
reported results of the 3-year activity of Inﬂuweb, that is an online
participatory surveillance platform for inﬂuenza. We estimated
(by extracting data from a ﬁgure through WebPlotDigitizer)62
that on average (mean of 3 seasons, range 29–41%) 38.6% of Ital-
ian65-year-olds reported to seekmedical service. Since we could
not identify any Italian population-based study or surveillance
system that would report elderly-speciﬁc data on hospitalizations
due to laboratory-conﬁrmed inﬂuenza and its complications, data
from the US surveillance system FluSurv-NET63 were adapted to
the Italian situation. By averaging the available seasonal data on
the cumulative hospitalization rate, it was possible to ﬁgure out a
rate of 111.8 per 100.000 elderly people. By applying this rate to
the target population, we could estimate a total of 14,947 expected
hospitalizations among the Italian elderly. However, the number
obtained is undoubtedly an underestimate for different reasons,
including a relatively low probability of being tested for inﬂuenza
in hospital and far from optimal polymerase chain reaction (PCR)
test sensitivity among the elderly (on average 63.5%).64 In order to
partially address this issue, we applied the following correction
formula: Nhospitalizations corrected D Nhospitalizations expected £ 1/Sensiti-
vityPCR.
28,64 This resulted in 23,539 hospitalizations. Considering
the attack rate of 5.4% and a likelihood of developing any inﬂu-
enza related-complication of 10.9%,53 the probability of hospitali-
zation for the whole elderly population would be 29.9%. To
establish risk category-speciﬁc probabilities of hospitalization, we
ﬁrst assumed that, like in the case of complications,53 the elderly
at high risk have a 1.3-hold higher likelihood of being hospitalized.
Then, we applied the formula (Plow risk £ h) C [Phigh risk £ (1.3£
h)]D 29.9%, where h is risk of hospitalization among the low-risk
elderly, and ﬁgured out the estimates of interest (low-risk: 26.4%;
high-risk: 34.3%). Again, a range of §20% was retained adequate
for the purpose of sensitivity analysis.
Inﬂuenza-related mortality. The probability of death fol-
lowing inﬂuenza is one of the most uncertain parameters in
economic modelling since its estimates vary greatly among sin-
gle observational studies.43,44,53,65,66 This high variability is
linked to various factors, including study design and methodol-
ogy, setting, timeframe and many others. The commonly cited
inputs are based on the so-called “excess mortality” that, by
using various statistical techniques, measures an excess number
of deaths observed during an inﬂuenza season. However, such
an approach has been criticized67 for several reasons. Indeed,
an increased winter mortality in the elderly is not uniquely
determined by the inﬂuenza virus. For instance, the human
respiratory syncytial virus (RSV), that often mimics inﬂuenza,
causes a signiﬁcant burden in different age-classes including
the elderly.68 The uncertainty is further ampliﬁed by the fact
that large population-based studies usually do not stratify mor-
tality data by vaccination status.
For all these reasons it was decided to adopt a conservative
approach. First, it was assumed that people may die only in
hospital. Then we identiﬁed the study by Arriola et al.66 as a
source of data since it explicitly reported mortality data among
both vaccinated and non-vaccinated elderly individuals. In par-
ticular, they registered 23 deaths out of 600 hospitalized non-
vaccinated people aged 65 years. Given that >90% of enrolled
patients had at least one underlying medical condition, it was
assumed that the reported probability of death (3.8%) would
refer to the elderly at high risk. For the low-risk elderly, the
parameter was deﬂated to 3.6%, by applying a correction factor
derived from a ratio of the probability of death among low-
and high-risk elderly reported by Meier et al.53 The assumed
parameters are consistent with mortality data following hospi-
talization among PCR-positive elderly demonstrated by Puig-
Barbera et al.69 For the sensitivity analysis we used the ranges
of 1.2–11.2% and 1.2–12.2% for the low- and high-risk, respec-
tively. The high limit was derived from Meier et al.,53 while the
low one was reduced by approximately 3 times considering the
Table 2. Demographic, epidemiological and clinical input parameters, by risk category.
Low-risk elderly High-risk elderly
Range Range
Parameter (probability) Base case Low High Base case Low High Ref
Risk category .5590 .4470 .6710 .4410 .3530 .5290 54
Vaccination coverage .5510 .4410 .6610 .6600 .5280 .7920 57, 58
Baseline attack rate of inﬂuenza .0540 .0210 .1060 .0540 .0210 .1060 17, 59
GP visit .3860 .2900 .4100 .3860 .2900 .4100 61
Complication Bronchitis .0269 .0238 .0302 .0346 .0305 .0390 53
Pneumonia .0104 .0086 .0126 .0131 .0106 .0160
URTI .0450 .0411 .0493 .0467 .0420 .0518
Cardiovascular .0009 .0004 .0017 .0080 .0061 .0103
CNS .0021 .0013 .0032 .0031 .0020 .0047
Renal .0005 .0002 .0011 .0016 .0008 .0028
Otitis media .0021 .0013 .0032 .0015 .0007 .0027
GI bleeding .0066 .0051 .0084 .0066 .0049 .0087
Hospitalization j Complication .2640 .2210 .3170 .3430 .2740 .4120 53, 63, 64
Death j Hospitalization .0360 .0120 .1120 .0380 .0120 .1220 53, 66
Abbreviations: CNS, central nervous system; GI, gastrointestinal; GP, general practitioner; URTI, unspeciﬁed respiratory tract infection.
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ratio between the point estimate and high limit of the two
groups. The relatively high range permitted us to partly address
the uncertainty around the mortality and highlight changes in
the economic outcome when considering epidemics of different
severity.
Table 2 summarizes demographic, epidemiological and clin-
ical input parameters used to populate the model.
Vaccine effectiveness
The average absolute (i.e. against no vaccination) VE of
TIV against laboratory-conﬁrmed inﬂuenza among the
elderly was derived from the meta-analysis of Jefferson
et al.,30 being 58% (95% CI: 34–73%). It was assumed that
ID-TIV, MF59-TIV and QIV have a greater VE than TIV
(i.e. relative VE>0%). Indeed, in their regression model,
Coudeville et al.70 estimated that the relative VE of ID-TIV
vs TIV was 16.5% (95% CI: 12.7–20.1%). MF59-TIV has
been found71 to be 25% (95% CI: 2–43%) more effective
than TIV that produces an absolute VE of 72.5%. The latter
estimate perfectly coincides with the absolute VE of MF59-
TIV of 72% against laboratory-conﬁrmed inﬂuenza among
the Canadian community dwelling elderly observed by Van
Buynder et al.26
The relative advantage of QIV was imputed since, to the best
of our knowledge, there was not any efﬁcacy data of QIV in the
elderly. The imputation procedure was similar to that reported
earlier.31 The starting point was that of quantiﬁcation of the
frequency of B type isolates (both lineages) among the Italian
elderly. From the ad hoc elaborated elderly-speciﬁc Lombardy
data (from the Inter-University Research Center on Inﬂuenza,
which is one of the National inﬂuenza surveillance networks),
it was possible to establish an average (across 13 seasons) isola-
tion rate of B strain virus of 17.9%. Then, by assuming an aver-
age level of B lineage mismatch of 60.1%31 and a relative
efﬁcacy of QIV vs TIV against the mismatched B lineage of
35%,72,73 it was possible to estimate, by weighting the above
probabilities, a surplus in VE of QIV vs TIV of 3.8%. For the
sensitivity analysis the range 58.0–64.3% was used since it
would reﬂect hypothetical scenarios of complete B strain match
and mismatch.
In other words, the number needed to vaccinate (NNV) in
order to avoid one laboratory-conﬁrmed inﬂuenza case in the
Italian elderly (when the baseline attack risk is .054) was 32, 28,
26 and 30 for TIV, ID-TIV, MF59-TIV and QIV, respectively.
Costs
Considering the adopted Italian NHS perspective, only
direct medical costs were taken into account; these are
reported in Table 3. The acquisition costs of all vaccines
considered ex-factory prices,31 while the cost of vaccine
administration was set to €6.16.74,75 Costs relative to the
outpatient treatment of inﬂuenza complications were
adapted from Marchetti et al.76 Given that in Italy the hos-
pital care is ﬁnanced according to diagnosis-related groups
(DRGs), DRG reimbursement tariffs were considered the
best choice for most complications requiring in-hospital
treatment.31,77 In particular, we applied DRG tariffs for
bronchitis, pneumonia, URTIs, renal complications, otitis
media and GI bleeding (DRGs 097, 090, 080, 316, 069 and
175, respectively). By contrast, given a multiplicity of clini-
cal presentations, and therefore DRGs, of cardiovascular
and CNS complications, we used the relative costs estimated
by Iannazzo17 that are weighted by the frequency DRGs.
Disutilities
It has previously been estimated,78,79 through the use of a stan-
dardized tool, that the annual utility loss for an episode of inﬂu-
enza is .0078. Utility loss for bronchitis (.00904), pneumonia
(.01041), URTIs (.00904), otitis media (.01382) and cardiovas-
cular complications (.1) were extracted from Mullikin et al.,18
while disutilities for renal and CNS complications (.0337 and
.0375 if treated in outpatients and inpatients regimens, respec-
tively) from Rotheberg et al.80
Sensitivity analysis
The head-to-head comparisons deemed cost-effective under-
went the sensitivity analysis. Different techniques were carried
out in order to verify robustness of the base case and identify
the main drivers of ICERs. First, the one-way deterministic sen-
sitivity analysis was carried out by altering (according the
above-described ranges) single parameter inputs. Then, PSA,
which allows to check the joint effect of uncertainty, with
10,000 Monte Carlo iterations was performed. In the PSA, beta
distributions were associated to demographic, epidemiological
and clinical features of inﬂuenza, while gamma distributions
were associated to costs and disutilities.
Disclosure of potential conﬂict of interest
Preliminary data of this study were presented at ESWI inﬂuenza confer-
ence (Riga, 10–13 September 2017) by SC who received a travel grant from
Seqirus srl.
Table 3. Cost parameter inputs used in the model.
Cost category Cost, € Ref
TIV ex-factory pricea 5.35 31
MF59-TIV ex-factory price 6.99
ID-TIV ex-factory price 6.99
QIV ex-factory price 11.08
Vaccine administration 6.16 75
GP visit 20.66 74
Outpatient treatment of complications (except for otitis media) 80 76
Outpatient treatment of otitis media 50 76
Bronchitis (DRG 097) 1,832 31, 77
Pneumonia (DRG 090) 2,291 31, 77
URTI (DRG 080) 4,422 31, 77
Cardiovascular complications (weighted mean DRGs) 3,544 17
Renal complications (DRG 316) 3,734 31, 77
CNS complications (weighted mean DRGs) 3,507 17
Otitis media (DRG 069) 1,247 31, 77
GI bleeding (DRG 175) 2,091 31, 77
a The ex-factory price of TIV is a weighted (by the volume sold) average of the
available brands in Italy.
Abbreviations: CNS, central nervous system; DRG. Diagnosis related group; GI, gas-
trointestinal; GP, general practitioner; ID-TIV, intradermal trivalent inactivated
vaccine; MF59-TIV, MF59-adjuvanted trivalent inactivated vaccine; QALY, quality-
adjusted life year; QIV, quadrivalent inactivated vaccine; URTI, unspeciﬁed respi-
ratory tract infection.
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